About The Author

Luca Mologni currently works at the School of Medicine and Surgery, Università degli Studi di Milano-Bicocca. Luca does research in Medicinal Chemistry, Pharmacology and Cell Biology. Their current project is 'Resistance to ALK inhibitors'.

Molecular Analysis Of Leukemia Patients By Next Generation Sequencing Predicts Targeted Therapy Outcome

Imatinib (Gleevec/Glivec, Novartis Pharma) is an oral drug developed to fight a particular type of blood cancer, termed Chronic Myeloid Leukemia (CML), in which there is an abnormal expansion of white blood cells number. At the molecular level, CML is caused by the formation of an aberrant chromosome, called the Philadelphia chromosome (Ph), which contains